Publications in collaboration with researchers from Complexo Hospitalario Universitario de Ferrol (12)

2023

  1. Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry

    ESC Heart Failure, Vol. 10, Núm. 2, pp. 1193-1204

2020

  1. Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping

    Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 12, pp. 3517-3524

2018

  1. Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: Results of the neurocognitive substudy of the SALT randomized clinical trial

    Journal of Antimicrobial Chemotherapy, Vol. 73, Núm. 9, pp. 2444-2451

2017

  1. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2016

  1. Validation of the 'Test of the Adherence to Inhalers' (TAI) for Asthma and COPD Patients

    Journal of Aerosol Medicine and Pulmonary Drug Delivery, Vol. 29, Núm. 2, pp. 142-152

2015

  1. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

2012

  1. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-for the treatment of chronic hepatitis C in HIV-infected patients: The PERICO trial

    Journal of Infectious Diseases, Vol. 206, Núm. 6, pp. 961-968

2009

  1. Sustained ventricular arrhythmias in unstable angina patients: Results of the ARIAM database

    Medical Science Monitor, Vol. 15, Núm. 6

2008

  1. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903

    Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092

  2. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens

    HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313

2006

  1. Bloqueo auriculoventricular en la angina inestable. Resultados del registro ARIAM

    Medicina Intensiva, Vol. 30, Núm. 9, pp. 432-439

  2. Orlistat reduce la obesidad abdominal. Un metaanálisis

    Revista Espanola de Obesidad, Vol. 4, Núm. 5, pp. 295-300